The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:1373-1375 March 29, 2007 Number 13
NextNext

Bevacizumab for Non–Small-Cell Lung Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Sandler, A.
-PubMed Citation
To the Editor: In their report on chemotherapy plus bevacizumab for non–small-cell lung cancer, as compared with chemotherapy alone, Sandler and colleagues (Dec. 14 issue)1 conclude that the addition of bevacizumab to paclitaxel and carboplatin has a significant survival benefit but is associated with an increased risk of treatment-related death. According to their results, 12 patients need to be treated to prevent one death at 1 year, at the price of an excess of one death from toxic effects for every 24 patients treated. Clearly, the balance between benefit and risk is questionable.


Marina Chiara Garassino, M.D.
Ospedale Fatebenefratelli e . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.